4.16

0.95% -0.04

Lixte Biotechnology Holdings Inc (LIXT)

Overview News Price History Financials Discussions Forecast Stock Split

Lixte Biotechnology Holdings Inc stock is traded at $4.16, with a volume of 60,450. It is down -0.95% in the last 24 hours and up +1.46% over the past month. Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Previous Close:

$4.20

Open:

$4.1801

24h Volume:

60,450

Relative Volume:

0.48

Market Cap:

$26.09M

Revenue:

Net Income/Loss:

$-4.69M

P/E Ratio:

-1.7854

EPS:

-2.33

Net Cash Flow:

$-3.81M

1W Performance:

-1.19%

1M Performance:

+1.46%

6M Performance:

+199.28%

1Y Performance:

+108.00%

1-Day Range:

$4.055

$4.30

1-Week Range:

$3.9283

$4.80

52-Week Range:

$0.64

$6.26

Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile

Name

Lixte Biotechnology Holdings Inc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

310 203 2902

Address

433 PLAZA REAL, BOCA RATON

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

LIXT's Discussions on Twitter

Compare LIXT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LIXT Lixte Biotechnology Holdings Inc	4.16	26.34M	0	-4.69M	-3.81M	-2.33
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News

Dec 04, 2025

Is Lixte Biotechnology Holdings Inc. (8640) stock a buy on weaknessJuly 2025 Institutional & Intraday High Probability Alerts - Newser

Dec 04, 2025

What sentiment indicators say about Lixte Biotechnology Holdings Inc. stockJuly 2025 EndofMonth & Fast Momentum Entry Tips - Newser

Dec 04, 2025

Is Lixte Biotechnology Holdings Inc. (8640) stock undervalued historicallyQuarterly Trade Summary & Real-Time Volume Surge Alerts - Newser

Dec 04, 2025

Can Lixte Biotechnology Holdings Inc. stock deliver consistent earnings growthJuly 2025 Closing Moves & Free Community Supported Trade Ideas - Newser

Dec 04, 2025

Will Lixte Biotechnology Holdings Inc. (8640) stock rise with strong economy2025 Breakouts & Breakdowns & Fast Entry and Exit Trade Plans - Newser

Dec 03, 2025

Dec 02, 2025

Will Lixte Biotechnology Holdings Inc. stock maintain momentum in 2025Weekly Trade Review & Verified Short-Term Plans - Newser

Dec 02, 2025

Nov 27, 2025

There is no doubt that Lixte Biotechnology Holdings Inc (LIXT) ticks all the boxes. - Setenews

Nov 27, 2025

Nov 25, 2025

Lixte Biotechnology Acquires Liora Technologies for Growth - TipRanks

Nov 25, 2025

Lixte Biotechnology shares slide following purchase of UK-based Liora - MSN

Nov 25, 2025

LIXTE Biotechnology acquires UK-based proton therapy developer Liora By Investing.com - Investing.com Nigeria

Nov 25, 2025

Lixte Biotechnology stock falls after acquiring UK-based Liora By Investing.com - Investing.com Canada

Nov 25, 2025

Lixte Biotechnology stock falls after acquiring UK-based Liora - Investing.com

Nov 25, 2025

LIXTE Biotechnology (LIXT) Expands with Acquisition of Liora Tec - GuruFocus

Nov 25, 2025

LIXTE Biotechnology acquires UK-based proton therapy developer Liora - Investing.com India

Nov 25, 2025

LIXTE Biotechnology Holdings, Inc. Completes Acquisition of Liora Technologies Europe Ltd. to Advance Proton Therapy Treatment for Cancer - Quiver Quantitative

Nov 25, 2025

LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment - InvestorNews

Nov 25, 2025

LIXTE (Nasdaq: LIXT) acquires Liora LiGHT proton therapy platform with $300M+ backing - Stock Titan

Nov 25, 2025

S&P 500, Dow and NASDAQ end day on positive note as Wall Street begins Thanksgiving week on high with boos - The Economic Times

Nov 25, 2025

Nov 24, 2025

Lixte Biotechnology announces $5M equity financing; shares down - MSN

Nov 24, 2025

Nov 23, 2025

Will Upside Catalysts Materialize for Vallabh Steels Limited in YEARGrowth Stock Opportunities & Small Capital Investment Tips - earlytimes.in

Nov 23, 2025

Nov 21, 2025

Earlyworks shareholders reject share issuance for acquisition, approve new directors and warrants By Investing.com - Investing.com Australia

Nov 21, 2025

Earlyworks shareholders reject share issuance for acquisition, approve new directors and warrants - Investing.com UK

Nov 21, 2025